atopix logo
  • Home
  • About
    • Company Overview
    • Management Team
  • R&D
    • Research Focus
    • CRTH2 Biology
    • Patients
    • Timapiprant
    • Clinical
  • Pressroom
    • Press Releases
    • Publications
    • Presentations
  • Contact

Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma

Timapiprant is a new molecular entity with an excellent safety profile demonstrated in over 800 subjects

CRTH2 receptor and its role in allergy

© 2018 Atopix Therapeutics Ltd

Identity by Franks and Franks